Sustained Release Excipients Market Size & Growth Forecast 2026–2035, By Segments (Product, Technology, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Sustained Release Excipients Market size was more than USD 1.56 Billion in 2025 and is set to grow at a 8.4% CAGR between 2026 and 2035, crossing USD 3.49 Billion by 2035. The industry revenue for 2026 is calculated at USD 1.67 billion.

• Base Year Value (2025): USD 1.56 Billion
• CAGR (2026-2035): 8.4%
• Forecast Year Value (2035): USD 3.49 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Sustained Release Excipients Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America led the market in 2025 due to its mature pharmaceutical manufacturing base, established formulation expertise, and consistent adoption of controlled-release drug formulations in commercial production.
  • Asia Pacific is projected to grow at a 9.49% CAGR, driven by expanding pharmaceutical manufacturing, greater use of advanced formulations, and rising investment in modified-release drug development.

• Segment Momentum:

  • Polymers held a 47.59% share in 2025 because they provide consistent control over drug release, support established manufacturing processes, and help developers create convenient extended-release formulations.
  • Transdermal is the fastest-growing technology as demand rises for non-invasive drug delivery systems that improve patient convenience, adherence, and sustained therapeutic exposure.

• Market Expansion Drivers:

  • Growing demand for controlled-release formulations improving patient compliance in chronic disease treatment.
  • Expanding geriatric and pediatric populations increasing adoption of sustained-release oral dosage systems.
  • Rising partnerships in advanced oral drug delivery technologies accelerating excipient innovation pipelines.

• Leading Market Participants:

  Top companies in the sustained release excipients market include BASF SE (Germany), Evonik Industries AG (Germany), Ashland Inc. (United States), International Flavors & Fragrances Inc. (United States), Croda International Plc (United Kingdom), Gattefossé SAS (France), Merck KGaA (Germany), Roquette Frères S.A. (France), Colorcon Inc. (United States), DuPont de Nemours, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 1.56 Billion
  • 2026 Market Size: USD 15.2 billion
  • Projected Market Size: USD 3.49 Billion by 2035
  • Growth Forecasts: 8.4% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Polymers (Product) | Targeted Delivery (Technology) | Oral (Route of Administration)
  • Emerging Opportunity Segment: Polymers (Product) | Transdermal (Technology) | Transdermal (Route of Administration)

Market Growth Drivers and Industry Trends

Growing demand for controlled-release formulations improving patient compliance in chronic disease treatment

As chronic conditions such as cardiovascular disease, diabetes, neurological disorders, and pain-related disorders require long-term medication use, pharmaceutical companies are placing greater emphasis on dosage formats that reduce dosing frequency and stabilize therapeutic effect. This is directly driving demand for the sustained release excipients market, since these excipients are central to designing tablets, capsules, and multiparticulate systems that control drug release over extended periods. In practice, the push for better patient adherence is influencing formulation decisions early in product development, with manufacturers selecting polymers, coatings, and matrix-forming excipients that can support once-daily or otherwise simplified regimens while maintaining consistent bioavailability, reinforcing market demand for technically differentiated sustained release platforms.

Expanding geriatric and pediatric populations increasing adoption of sustained-release oral dosage systems

Age-sensitive patient groups are reshaping oral drug formulation strategies, particularly where frequent dosing creates administration challenges, missed doses, or fluctuating therapeutic response. In the sustained release excipients market, this is encouraging market growth as drug developers seek oral dosage systems that improve convenience for older adults managing multiple medications and for pediatric patients who benefit from reduced dosing burden and more predictable drug exposure. The practical effect is stronger adoption of excipients that enable modified-release profiles while also meeting formulation requirements such as swallowability, taste masking compatibility, compressibility, and stability, making sustained release design a more integral part of lifecycle management and new product development.

Rising partnerships in advanced oral drug delivery technologies accelerating excipient innovation pipelines

Collaboration between excipient suppliers, drug developers, contract development and manufacturing organizations, and drug delivery technology firms is shortening the path from formulation concept to commercial application. For the sustained release excipients market, these partnerships are driving market development by accelerating the creation of specialized release-modifying materials tailored to poorly soluble APIs, high-drug-load formulations, and more complex oral delivery objectives. In practice, joint development programs improve access to application data, formulation know-how, and scale-up capabilities, which reduces adoption barriers for newer excipient systems and encourages pharmaceutical manufacturers to incorporate more advanced sustained release solutions into product pipelines.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Increasing demand for sustained-release drug formulations	2.80%	Short term (≤ 2 yrs)	North America, Europe	Medium	Fast
Technological innovations in excipient formulations	2.80%	Medium term (2–5 yrs)	North America, Asia Pacific	Low	Moderate
Expansion of pharmaceutical manufacturing in emerging markets	2.80%	Long term (5+ yrs)	Asia Pacific, Latin America	Low	Slow
Growing demand for controlled-release formulations improving patient compliance in chronic disease treatment	2.20%	High	North America, Europe	High	Near Term
Expanding geriatric and pediatric populations increasing adoption of sustained-release oral dosage systems	1.90%	Moderate	Asia Pacific, North America	High	Mid Term
Rising partnerships in advanced oral drug delivery technologies accelerating excipient innovation pipelines	1.60%	Moderate	North America, Europe, Asia Pacific	Emerging	Long Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional market share in 2025 for the sustained release excipients market, backed by its mature pharmaceutical manufacturing base and steady use of advanced drug delivery formulations across branded and generic production. The region’s leadership is strengthened by established formulation expertise, strong uptake of controlled-release oral dosage development, and the presence of manufacturers that routinely integrate specialized excipients into commercial-scale production. In practice, this creates consistent demand from drug developers seeking reliable release profiles, process efficiency, and regulatory familiarity when bringing sustained-release products to market.

Asia Pacific is projected to expand at a 9.49% CAGR over the forecast period in the sustained release excipients market, driven by rising pharmaceutical production capacity and increasing adoption of more sophisticated formulation approaches across regional manufacturing hubs. Growth is accelerating as companies move beyond basic generics into differentiated dosage forms that require excipients capable of controlling release performance and improving product consistency. This shift is translating into stronger regional demand from manufacturers investing in higher-value drug development, scale-up capabilities, and broader use of modified-release technologies in everyday production.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Developing
Cost-Sensitive Region	Low	High	Medium	High	High
Regulatory Environment	Restrictive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Strong	Strong	Moderate	Moderate
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	High	High	Medium	Medium
New Entrants / Startups	Moderate	Moderate	Moderate	Sparse	Sparse
Macro Indicators	Strong	Strong	Stable	Stable	Stable

Key Country Insights

United States

Advanced Drug Formulation

The U.S. sustained release excipients market is driven by pharmaceutical companies developing differentiated oral and injectable therapies. Manufacturers increasingly seek excipients that improve controlled drug delivery while supporting scalable and compliant production processes.

Japan

Precision Delivery Solutions

Japan emphasizes sustained release excipients for innovative pharmaceutical formulations requiring precise drug release profiles. Pharmaceutical developers increasingly integrate advanced excipient technologies to improve patient convenience and product differentiation.

South Korea

Biopharma Formulation Support

South Korea expands the use of sustained release excipients across innovative pharmaceuticals and contract manufacturing activities. Companies focus on excipient performance, formulation flexibility, and efficient production to support competitive drug development programs.

Germany

Formulation Quality Focus

Germany prioritizes sustained release excipients that enhance product consistency and manufacturing efficiency in pharmaceutical development. Companies continue investing in advanced formulation technologies that support reliable therapeutic performance and regulatory expectations.

France

Controlled Release Development

France supports sustained release excipient adoption through ongoing pharmaceutical formulation innovation and specialty medicine development. Manufacturers prioritize excipients that improve dosage performance while meeting evolving regulatory and quality standards.

Italy

Generic Formulation Enhancement

Italy utilizes sustained release excipients to strengthen the development of value-added generic medicines and specialty pharmaceutical products. Drug manufacturers increasingly adopt advanced excipient technologies to improve formulation efficiency and therapeutic consistency.

Segment Leadership and Growth Trends

  Product Segment Analysis: Polymers (Largest & Fastest-Growing Segment)

Polymers held a 47.59% share of the sustained release excipients market in 2025, reflecting their central role in controlling drug release profiles across a wide range of oral and specialty formulations. Their leadership is underpinned by practical formulation advantages, particularly the ability to modulate release rates with consistency while remaining compatible with established pharmaceutical manufacturing processes. The same operating strengths continue to support growth momentum in the sustained release excipients market, as drug developers favor excipient systems that can simplify formulation design, improve dosing convenience, and align with ongoing demand for extended-release products without requiring major process disruption.

Technology Segment Analysis: Targeted Delivery (Largest Segment) vs Transdermal (Fastest-Growing Segment)

Within the sustained release excipients market, targeted delivery accounted for a 24.6% share in 2025, making it the leading technology segment. Its position is supported by the practical value of directing active ingredients more precisely within the body while sustaining release over time, which helps improve therapeutic efficiency and supports the development needs of more specialized drug formulations. This combination of controlled release performance and application relevance keeps targeted delivery at the forefront of technology adoption in the market.

Transdermal is emerging as the fastest-growing technology segment in the sustained release excipients market because it aligns closely with rising demand for non-invasive drug administration and longer-duration dosing formats. Its momentum is being influenced by the practical benefit of maintaining controlled drug delivery through the skin while reducing reliance on conventional oral or injectable routes. Compared with alternative technologies, transdermal systems are experiencing stronger uptake where patient convenience, adherence, and steady drug exposure are becoming more important in formulation decisions.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Gelatin, Polymers, Minerals, Sugars, Alcohol, Chitosan	Polymers	Polymers
Technology	Targeted Delivery, Micro Encapsulation, Wurster Technique, Transdermal, Implants, Coacervation, Others	Targeted Delivery	Transdermal
Route of Administration	Oral, Intramuscular, Subcutaneous, Transdermal, Vaginal, Ophthalmic, Intravenous, Others	Oral	Transdermal

Competitive Landscape and Market Positioning

Leading companies in the sustained release excipients market:

1. BASF SE (Germany)

2. Evonik Industries AG (Germany)

3. Ashland Inc. (United States)

4. International Flavors & Fragrances Inc. (United States)

5. Croda International Plc (United Kingdom)

6. Gattefossé SAS (France)

7. Merck KGaA (Germany)

8. Roquette Frères S.A. (France)

9. Colorcon Inc. (United States)

10. DuPont de Nemours Inc. (United States)

The sustained release excipients market is growing with rising demand for advanced drug delivery systems. Formulation innovation is improving controlled-release performance and patient compliance. The sustained release excipients market continues to expand as pharmaceutical development becomes more targeted and efficient.

Industry Development/News

Company Name	Date	Key Development
Colorcon Inc, DuPont	Apr-19	Colorcon Inc entered a Controlled Release Alliance with DuPont to expand its functional film coating portfolio through the addition of Aquacoat modified-release products. The collaboration strengthens controlled-release formulation capabilities in pharmaceutical excipients, enhancing availability of advanced coating technologies used to improve drug delivery performance and formulation flexibility.
DuPont, International Flavors & Fragrances Inc	Feb-21	DuPont completed the merger of its Nutrition & Biosciences business with International Flavors & Fragrances Inc, consolidating its position in functional ingredients and delivery systems. The integration expanded the excipients portfolio, including controlled-release technologies, and strengthened downstream capabilities in pharmaceutical and nutraceutical formulation solutions.
Croda International Plc	Jun-23	Croda International Plc commenced construction of a 23,680 square feet pharmaceutical excipients manufacturing facility in Pennsylvania, United States. The expansion is intended to increase production capacity for drug delivery ingredients, supporting growing demand for functional excipients used in controlled and sustained-release pharmaceutical formulations and strengthening regional supply capabilities.